The record-setting Alexandria lab lease in San Diego showcases how biotech has few big tenants left to take empty spaces.

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

TSMC, which manufactures advanced semiconductors for clients including Nvidia ( NVDA) and Apple ( AAPL ), said it expects third-quarter revenue to reach between $31.8bn (£23.7bn) and $33bn, a 38% ...

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based drugmaker's revenue.

Entresto is considered a cornerstone of Divi’s innovator-driven custom synthesis portfolio, contributing close to 40 percent of the segment’s revenue.

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a blow to the Swiss company’s efforts to find new uses for the ...

Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s tariffs on imports.